gefitinib, Iressa (Discontinued in the US) (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

PREGNANCY: Gefitinib should not be used by pregnant women.

NURSING MOTHERS: It is not known whether gefitinib is secreted in human milk. Since there is a possibility of toxicity in nursing infants, it is recommended that breastfeeding be stopped if the mother is treated with gefitinib.

SIDE EFFECTS: About one in one hundred persons receiving gefitinib develop a potentially serious lung condition called interstitial lung disease that causes inflammation within the lung. Therefore, patients taking gefitinib who develop new or worsening cough, fever, or difficulty in breathing should contact their physician immediately.

Eye irritation has been observed in patients receiving gefitinib, and patients who develop the onset of new eye symptoms should contact their physician.

All patients taking gefitinib should seek medical advice promptly if they develop severe or persistent diarrhea, nausea, loss of appetite, or vomiting.

Reference: FDA Prescribing Information


Last Editorial Review: 7/23/2012



Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index